Dr. Anjani Jha is the Founder and CEO of MAA Laboratories, a specialty pharmaceutical company advancing nanoparticle-based drug products through its proprietary NanoCont™ continuous manufacturing platform. Under his leadership, the company is developing a pipeline of differentiated therapies that address critical unmet needs across multiple therapeutic areas. With over 20 years of experience in pharmaceutical R&D, technology transfer, and commercial manufacturing, Dr. Jha has led drug development programs from preclinical stages through to market launch. Prior to founding MAA Laboratories in 2015, he held scientific and leadership positions at GlaxoSmithKline (GSK), Pharmaceutics International (Pii), Rhodes Pharmaceuticals (a Purdue Pharma company), and the MIT–Novartis Center for Continuous Manufacturing, where he contributed to the design of the world’s first end-to-end continuous drug manufacturing system. Throughout his career, Dr. Jha has successfully developed and launched drug products across a broad range of therapeutic areas—including oncology, cardiovascular, respiratory, inflammation, pain, and ADHD—via the 505(b)(1), 505(b)(2), and ANDA regulatory pathways. He earned his Ph.D. from The Pennsylvania State University, completed postdoctoral research at MIT, and is a proud alumnus of IIT Kharagpur.

Surya Namburi leads Global Regulatory Affairs at MAA Laboratories, guiding the development and approval of the company’s innovative nanoparticle-based drug products across major global markets. With more than 20 years of regulatory leadership, he brings deep expertise in global submissions, GMP compliance, and regulatory strategy for complex generics and specialty products. Surya has overseen the submission of over 150 ANDAs to the U.S. FDA, including more than 30 oncology injectables, and has led 300+ EU marketing authorization applications via centralized, decentralized, and mutual recognition procedures. His regulatory track record spans approvals in the U.S., EU, Canada, Japan, China, Australia, and several emerging markets, with a consistent focus on inspection readiness, accelerated approvals, and strategic lifecycle management. Prior to MAA Laboratories, Surya held senior regulatory and R&D roles at leading pharmaceutical companies such as Biocon, Apotex, Eisai, Torrent, and Ranbaxy. His experience covers a wide range of dosage forms, including oral solids, lyophilized and non-lyophilized injectables, biosimilars, and pediatric formulations. He holds a Master’s degree in Pharmaceutics from The Tamil Nadu Dr. MGR Medical University and a Bachelor’s degree in Pharmacy from Bangalore University.

Eric Wesoloski is a globally respected pharmaceutical quality and compliance leader with over 30 years of experience across branded, generic, OTC, and biologic products. As Head of Quality and Compliance at MAA Laboratories, he oversees all aspects of clinical manufacturing quality, ensuring our investigational drug materials and facilities meet the highest standards set by the FDA and international regulatory authorities. Eric has led global quality operations and supported more than 100 inspections by agencies including the FDA, EMA, MHRA, ANVISA, PMDA, TFDA, and TGA. His expertise spans GMP compliance, QA/QC systems, inspection readiness, CDMO oversight, and global QMS implementation. Prior to joining MAA Laboratories, Eric held executive quality roles at Mylan, Sanofi Pasteur, Takeda, Piramal Critical Care, and AmerisourceBergen, where he built and managed global quality systems supporting clinical and commercial operations across the U.S., EU, Asia, and Latin America. Eric holds a B.S. in Biology from Gannon University and an MBA in Leadership & Management from Indiana University. He is an active member of PDA, ISPE, ASQ, and the FDA Metrics Committee.

Dr. Honoré is currently serving as the President of Aestus Partners. He is also serving as the founding member of the scientific advisory board at Forge Life Science and chairman of the board Dep-Xplora Aps and previously served as Vice President of Discovery Research. Dr. Honore also served as the Senior Executive Vice President at Novartis. Before Novartis, he served as the Vice President of Discovery Research at Novo Nordisk. As a pharma executive, Dr. Honore championed development of ideas to early clinical studies in cancer immunotherapy, alzheimer’s disease, anxiety, chronic pain, depression, epilepsy, female hormone replacement therapy, learning disorders, osteoporosis, Parkinson’s disease, stroke and schizophrenia. Dr. Honore contributed to more than 40 new molecular entities entering clinical development of which three were launched, and he managed budgets for a total of approximately $1B. Dr. Honore developed organizational models to obtain record pipeline productivity in several companies and entrepreneurial value creation by integration of research, clinical, marketing and financial stakeholders. He published more than 100 scientific journal articles and is an inventor on 23 patents. His Doctoral degrees in Medicinal Chemistry and Neurobiology and business training are from Harvard Business School and European Management Centre.

Dr. Shankar Hariharan is a seasoned pharmaceutical executive with over 30 years of experience in drug development, regulatory strategy, and specialty dosage form innovation. He currently serves as the Founder and CEO of Scientiure, a pharmaceutical R&D company focused on advancing complex generics, innovative formulations, and technology-enabled drug delivery solutions. Throughout his career, Dr. Hariharan has held senior leadership roles at Amneal Pharmaceuticals, Forest Laboratories, Par Pharmaceuticals, and International Development Research, where he directed global R&D and regulatory operations for both branded and generic portfolios. He is recognized for his deep expertise in formulation science, clinical pharmacology, lifecycle management, and global regulatory approvals, and has successfully led numerous NDA, ANDA, and hybrid submissions across the U.S., EU, and other major markets. Dr. Hariharan earned his Ph.D. in Pharmacy from Northeastern University in Boston and holds a Bachelor’s degree in Pharmacy from Banaras Hindu University in India.

Mr. Ed Bogart brings over 36 years of experience in the healthcare industry, advancing pharmaceuticals, biologics, and medical devices in the United States and Internationally. Mr. Bogart has held numerous executive positions in Pharmaceutical, Biopharma, Medical Device, USAF Medical Corps, companies’ with an expertise in the areas of pharmaceutical sales, hospital sales, academic medicine, government accounts (nationally & internationally),managed care, regional and national accounts, product management, product launches (IND, 505(b)(2), reformulations, and orphan), new product launches, pharmaco-economics, health outcomes/health economics (data modeling), clinical trail funding/sourcing, contract department design/buildout and management. Price analytics, price scheduling, negotiations across all business segments for market access. Specialized in working with all government agencies (DoD, CMS, CDC, & VA Health System). Mr. Bogart possesses a thorough understanding of every aspect of reimbursement strategies. Mr. Bogart received a BS in Healthcare Administration Management from Park University in Parkville, MO.